Alector Inc.

Another day, another Alzheimer’s failure. This time it is the turn of Alector, whose AbbVie-partnered anti-TREM2 antibody, AL002, failed in Phase II, and while this is not quite as big a catastrophe

AbbVie is paying $1.4bn in cash for privately held Aliada Therapeutics and its sole clinical candidate – but if ALIA-1758 proves to be a best-in-class disease-modifying therapy for Alzheimer’s disease

While a handful of new Alzheimer’s drugs have made it to market in recent years, some groups are working on other forms of dementia. One such is Vesper Bio , whose sortilin inhibitor VES001 generated

Amidst a continued chilly environment for novel approvals, the US FDA’s breakthrough therapy designation (BTD) program has been generating heat this month, with seven new awards announced in February,